NASDAQ: CYTH
cyclotherapeutics.com

Corporate Presentation

Forward-Looking Statements

Some of the information in this presentation relates to future events or future business and financial performance. Such statements constitute forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such statements can be only predictions and the actual events or results may differ from those discussed due to, among other things, the risks described in the public filings and other publications of Cyclo Therapeutics, Inc. Forward-looking statements are identified by words such as “anticipates”, “projects”, “expects”, “plans”, “intends”, “believes”, “estimates”, “target”, and other similar expressions that indicate trends and future events.

The market data and certain other statistical information used throughout this presentation are based on independent industry publications, governmental publications, reports by market research firms or other independent sources. Some data are also based on the Company’s good faith estimates. In addition, this presentation includes summaries of scientific activities and outcomes that have been condensed to aid the reader in gaining general understanding.

The information about Cyclo Therapeutics, Inc. and its subsidiaries is solely for information purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any state.

Factors that could cause the Company’s results to differ materially from those expressed in forward looking statements include, without limitation, the Company’s need for additional capital; the Company’s reliance on its Trappsol® Cyclo™ product, which may never receive regulatory approval; the Company’s ability to commercialize any of its proposed drug products if it receives regulatory approval; the outcome of the Company’s clinical trials, which may not support the Company’s product claims or may result in adverse side effects; the cost and timing of the Company’s clinical trials; the Company’s reliance on third parties to conduct clinical trials and to produce its products; and other risks associated with being a clinical stage biotechnology company.

Platform Technology Pipeline:

Trappsol® Cyclo™ allows for a multiple shots on goal model

Program	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Milestones
Trappsol® Cyclo™	**Niemann-Pick Disease Type C**					TransportNPC™ **(Pivotal Phase 3 Study)** Site activation ongoing and currently enrolling patients
Trappsol® Cyclo™	**Alzheimer's Disease**					Open IND for Phase 2 study



Orphan Drug Designation in U.S. | Fast Track Status in U.S.| Potential for Priority Review Voucher (PRV) in U.S

Orphan Designation in EU | EMA Pediatric Investigational Plan Adopted

Leadership Team with Proven Experience

N. Scott Fine
Chief Executive Officer & Director

Green Mountain Coffee · Keurig · GVN Global Virus Network

Joshua M. Fine
Chief Financial Officer

ICAGEN (a Ligand company) · EGE

Lise Lund Kjems, MD, PhD
Chief Medical Officer

Albireo · aldeyra · Intarcia · Bylvay (odevixibat) · Novartis

Michael Lisjak
Chief Regulatory Officer

Pfizer · Sanofi Genzyme · accenture

Sharon H. Hrynkow, Ph.D.
Chief Scientific Officer

NIH · GVN Global Virus Network

Russ Belden
Acting Chief Commercial Officer

Genentech

Jeffrey L. Tate, Ph.D.
Chief Operating Officer, Chief Quality Officer & Director

University of Minnesota · Pulse Combustion Systems · natural biologics

Lori McKenna Gorski
Global Head of Patient Advocacy

Sanofi Genzyme · IONIS · PTC Therapeutics

Niemann-Pick Disease Type C

Ongoing Pivotal TransportNPC™ Phase 3 Study

NPC: A Debilitating Disease with Fatal Outcomes

- Rare, fatal and progressive genetic disorder effecting the brain, liver, spleen and lungs.
- Characterized by a defect in the NPC1 protein
- Cholesterol and lipids accumulate in cells of major organs and tissues
- Leading to cell and tissue dysfunction

0 U.S. Approved NPC Therapies

1 EU Approved Therapy with no systemic effects

Market Opportunity[1]

United States: $300 Million | Worldwide: $600 Million

Incidences

1/100,000 (~35 per year in U.S.)

Of Diagnosis

~ 3% are age 3 and below
~ 97% are age 3 and above
~ 60% age 16 and above

Median Survival

Early Infantile (2m-2): 4.6y

Late Infantile (3-6): 9.4y

Juvenile (7-15): 15.4y

Adolescent/Adult (16+): 12.2y

1: Data on file Cyclo Therapeutics
*Scope: United States + 79 other countries; *Commissioned Tessellon Inc – former Kantar Health experts with 25+ years of epidemiology and forecasting experience, (www.Tessellon.com); *Exhaustive literature search with a broad range of MESH terms.

Trappsol® Cyclo™

Enables the Effective Transport of Cholesterol Out of Cells



Maetzel et al., 2014

Cholesterol as measured by Filipin staining at Baseline and after 7 doses over 14 weeks



The lack of light blue represents the clearing of cholesterol from cells

Maetzel et al., 2014
Source : Study 101

Trappsol® Cyclo™ Summary of Completed Clinical Studies in NPC

Study 101

Phase 1 study in NPC patients age 18 years and older showed Trappsol® Cyclo™ was well-tolerated with an acceptable safety and tolerability profile

- After IV infusion, the drug is detectable in the cerebrospinal fluid within hours after the start of infusion
- Cholesterol synthesis and metabolism affected, and cholesterol cleared from cells, mimicking effects from nonclinical studies (in vitro and in vivo) in NPC models

Study 201

Consistent pharmacodynamic effects and safety profile observed in a 48-week Phase 1/2 study in NPC patients aged 2 years and older

- 100% of patients assessed by treating physicians to be either stable or improved
- 88% (8 of 9 patients who completed the study), experienced clinically meaningful improvements in one or more efficacy endpoints, assessed by the 17 Domain NPC Severity Scale
- Based on totality of data from the Phase 1 and Phase 2 studies, the 2000 mg/kg dose was selected for the Phase 3 study

Transport NPC™

Ongoing Pivotal Phase 3 Study in Niemann-Pick Disease Type C

Double-blind, Randomized, Placebo-controlled, Parallel-group study and
is currently the most advanced clinical research program underway to identify a treatment for NPC

Number of Subjects	93	
Current Sites	23 across 9 countries	United States, United Kingdom, Italy, Germany, Spain, France, Poland, Israel, and Australia
Duration	96-week trial, with Interim Analysis at 48 weeks	
Dose	2000 mg/kg via IV infusion	
Primary Endpoint	NPC Composite Severity Score	
Secondary Endpoints	SCAFI, Swallow, Vineland-2	
Exploratory Endpoints	Inclusive of Speech, Liver and Lung function	

We Have the Only Active Late-Stage Clinical Program in NPC

Company	Indication	Preclinical	Phase 1	Phase 2	Phase 3	Potential Indication (Systemic and Neurological)	Safety Profile	Summary
cyclo therapeutics	Trappsol® Cyclo™ (Intravenous every 2 weeks, Home infusions)							Met all primary endpoints of the Ph1 and Ph1/2 showing favorable safety and efficacy. Ph3 currently enrolling and additional site activation ongoing.
ACTELION	Zavesca* (Oral 3 times daily)							FDA: Data did not support benefit risk. Off-label in US. EMA: Approved January 2009.
ORPHAZYME	Arimoclomol (Oral 3 times daily)							FDA: CRL received June 18, 2021, noting additional data required to support benefit risk. EMA: CHMP Opinion and potential MAA anticipated Q1 2022 as Adjunct Therapy.
IntraBio	IB1001 (Oral 3 times daily)							Met with FDA, EMA and UK, Phase 3 study required, 6-month placebo-controlled crossover trial with approximately 50 patients (4 years of age and above). Study enrollment anticipated H1 2022.
Mandos Health	Adrabetadex (VTS-270) (Intrathecal every 2 weeks)							MNK concluded program 20-Jan-2021 noting the benefit risk is negative. Mandos received Court Approval to buy from MNK 29-Jun-2021. FDA has not found drug to be safe and effective for use to treat NPC1 or for any other use.
ESCAPE BIO	ESB1609 (Oral, brain-penetrant					TBD	TBD	Selective sphingosine-1-phosphate 5 (S1P5) receptor agonist.

Differentiation Key: - Optimal - Moderate - Weak

Alzheimer's Disease

Open IND for Phase 2 study

Alzheimer’s Disease
The Most Common Form of Dementia

An irreversible, progressive neurologic disorder that slowly degrades memory, thinking and social skills that affects a person's ability to function independently.

Similarities with NPC

Cognitive decline

Elevated levels of tau

Amyloid plaques

- Affects more than 5 million people in the U.S.[1]
- 6th leading cause of death in the U.S. [1]
- 500,000 new cases every year[2]
- 13.8 million cases projected by 2050[1]

1. https://www.alz.org/alzheimers-dementia/facts-figures
2. https://www.brightfocus.org/alzheimers/article/alzheimers-disease-facts-figures

Commonality Across Target Neurodegenerative Diseases

Alzheimer's Disease

Secondary Tauopathy



Niemann-Pick Disease Type C

Primary Tauopathy



Biologic Similarities

Cholesterol Accumulation in Regions of Brain

Elevated Levels of Tau in CSF

Amyloid Plaques in the Brain

Disease Manifestation

Cognitive decline / dementia
Premature death
Clumsiness
Progressive motor symptoms
Ataxia, dystonia, dysarthria, dysphasia
Psychiatric signs: psychosis, depression
Weight loss

Disease Manifestation

Progressive cognitive decline / early dementia
Premature death
Clumsiness, gait disturbance
Delayed motor milestones
Progressive: ataxia, dystonia
Seizures
Weight loss

Trappsol® Cyclo™ for the Potential Treatment of Alzheimer's Disease

Targeting Reduction of Amyloid Beta and Tau

Received IND Clearance from the U.S. FDA to Advance Phase 2 Study

Preeminent Neuroscientist and World-Renowned Researcher,
Cynthia A. Lemere, PhD Senior Advisor for Advancement of Alzheimer's Disease Asset

Positive Results in Alzheimer Patient Under Compassionate Use Program

FDA authorized use of Trappsol® Cyclo™ in geriatric patient

- 18 months of monthly IV infusion
- Disease did not progress
- Family reported less volatility and greater word-finding ability

18 months of data has led to development of Phase 2 protocol

Alzheimer's Mini-Mental State Evaluation Performance[1]



*"The patient has shown cognitive and neurologic stability in serial examinations during this study that indicates possible benefit as there would be an expected measurable cognitive and functional decline over an 18-month period in persons with Alzheimer's disease dementia, "*Treating Physician

*Treating physician reported the 18-month score as a range between 24-26

1: Rate of MMSE decline in AD patients: Eldholm, RS et al, J. Alz. Disease, 61: 1221, 2018. Suh, GH et al., Intl. J. Geriatric Psychiatry, 19(9): 817, 2004.

Corporate Overview

Financial Snapshot - Nasdaq: CYTH



1: Pro-forma at 9/30: Included proceeds from public offering on 11/17/2021
2: As of December 20, 2021 with a closing price of $4.15

Investment Summary

Leveraging over 3 decades of experience with cyclodextrins to advance clinically de-risked programs towards approval in diseases with unmet medical need

Platform technology has demonstrated to be safe and effective with over 10 years of patient exposure

TransportNPC™

Global site activation ongoing and currently enrolling patients in Pivotal Phase 3 study in Niemann-Pick Disease Type C

Received IND Clearance to Advance Phase 2 Study in Alzheimer's Disease

Well funded through key value-driving clinical and regulatory milestones

Trappsol® Cyclo™ is a platform technology with opportunity to expand into multiple indications

Leadership team with proven track-record in execution and value creation

NASDAQ: CYTH
cyclotherapeutics.com

cyclo therapeutics

Thank you!